A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants

StatusCompleted
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 5 more changesShow less
    • Primary completion date changed from estimate of Jul 15, 2025 to Jul 15, 2024
    • Enrollment target: estimated 131 to confirmed 128
    • Study completion date changed from estimate of Dec 30, 2025 to Sep 30, 2024
    • Eligibility criteria expanded, about 44 words
    • Site details revised
  2. Study site revisedv2
  3. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
MindRank AI Ltd
6 trials monitored
See all monitored trials
Obesity
3,898 trials monitored
See 160 trials at risk
To investigate the safety and tolerability after single and multiple ascending doses of MDR-001 Tablets administered orally in healthy participants and obese/ overweight participants.
Trial Details
NCT Number NCT06778850
Lead Sponsor MindRank AI Ltd
Conditions
(from sponsor)		 Overweight and Obese Volunteers
Related terms Overweight
Enrollment 128 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov